RESUMO
Background: There have been few studies comparing the effects of high- and low-dose rocuronium during cesarean section by directly measuring the concentration. Therefore, we conducted a study to examine the blood concentrations and clinical effects of both doses of rocuronium on mothers and fetuses. Methods: Eighteen patients were randomly assigned to two groups: C Group (0.6 mg/kg), and H Group, (1.0 mg/kg). The primary outcome was the comparison of umbilical vein rocuronium concentration between two groups. We assessed ease of intubation, time from rocuronium administration to some TOF points, post-anesthesia care unit (PACU) stay time, infused remifentanil dose, maternal rocuronium concentration, and Apgar scores. Results: No differences were observed in demographic data, ease of intubation, PACU stay time, 1 min Apgar scores, umbilical venous blood gas analysis between both groups. However, the time from rocuronium administration to T3 disappearance was shorter (p=0.009) and time to T1 and T2 reappearance were longer (p=0.003, p=0.009) in H group than that in C group. The administered remifentanil dose (p=0.042) was lower in the H group than in the C group. Rocuronium concentrations in the umbilical vein (p=0.004) and maternal vein before cord clamping (p=0.002) and at discharge (p<0.001) were also found to be higher in the H group than in the C group. Conclusions: We observed no prolongation of PACU stay, and no differences in Apgar scores in H group compared to C group. It suggests that 1.0 mg/kg of rocuronium has no negative effects on the fetus and mother in cesarean section.
Assuntos
Anestesia Geral , Cesárea , Fármacos Neuromusculares não Despolarizantes , Rocurônio , Humanos , Rocurônio/administração & dosagem , Cesárea/métodos , Feminino , Gravidez , Anestesia Geral/métodos , Adulto , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Remifentanil/administração & dosagem , Índice de Apgar , Relação Dose-Resposta a Droga , Androstanóis/administração & dosagem , Androstanóis/sangueRESUMO
BACKGROUND The aim of this study was to compare androgen levels, endocrine and metabolic indices, and clinical findings in women with polycystic ovary syndrome (PCOS) in Uygur and Han ethnic groups from Xinjiang Province, China. MATERIAL AND METHODS Between January 2016 to May 2017 clinical data were collected from Uygur (N=82) and Han (N=100) women diagnosed with PCOS, including age, body mass index (BMI), the Ferriman-Gallwey (mFG) hirsutism score, and waist-to-hip ratio (WHR). Blood samples obtained from all study participants were used to measure androgenic steroid levels, including androgen, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone (DHT), and the free androgen index (FAI). Endocrine indices measured included sex-hormone binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), and prolactin (PL). Metabolic indices measured included insulin, glucose, total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), triglyceride (TG), and low-density lipoprotein (LDL). RESULTS The FAI in Uygur women with PCOS (4.89) was significantly increased compared with Han women with PCOS (2.78) (p<0.05); androgen levels were significantly correlated with the FAI, glucose, insulin, TC, HDL, and LDL (p<0.05); androstenedione levels were positively correlated with glucose and insulin levels (p<0.05). In Han women with PCOS, androgen levels were negatively correlated with TG levels and positively correlated with TC levels (p<0.05); the FAI was positively correlated with glucose and insulin levels (p<0.05). CONCLUSIONS There were significant differences in androgen levels, endocrine, and metabolic indices in women with PCOS between the Uygur and Han ethnic groups from Xinjiang Province in China.
Assuntos
Síndrome do Ovário Policístico/metabolismo , Síndrome do Ovário Policístico/fisiopatologia , Adulto , Androgênios/análise , Androgênios/sangue , Androstanóis/análise , Androstanóis/sangue , Glicemia/metabolismo , Índice de Massa Corporal , Pesos e Medidas Corporais , China , Etnicidade/genética , Feminino , Gonadotropinas Hipofisárias/análise , Gonadotropinas Hipofisárias/sangue , Humanos , Insulina/sangue , Resistência à Insulina , Lipoproteínas/análise , Lipoproteínas/sangue , Obesidade/sangue , Testosterona/sangue , Triglicerídeos/sangueRESUMO
AIM: 5α-androst-3ß,5,6ß-triol is a novel ischemic stroke drug under clinical development. The objective of this study was to develop and validate a simple ultraperformance liquid chromatography tandem mass spectrometry method for 5α-androst-3ß,5,6ß-triol in human plasma and its application in clinical pharmacokinetic study. Methodology & results: After being pretreated using an automatized solid-phase extraction procedure, plasma sample was separated on a Waters® Acquity™ BEH C18 column (2.1 × 50 mm id, 1.7 mm) by an Acquity UPLC system and detected by an API 5500 triple quadrupole mass spectrometer, which was validated following international guidelines. CONCLUSION: A simple method was successfully validated over a concentration range of 2.00-500 ng/ml for 5α-androst-3ß,5,6ß-triol and applied to investigate its plasma pharmacokinetic profiles in healthy Chinese subjects.
Assuntos
Androstanóis/sangue , Cromatografia Líquida de Alta Pressão/métodos , Espectrometria de Massas em Tandem/métodos , Humanos , Limite de Detecção , Reprodutibilidade dos Testes , Extração em Fase Sólida/métodos , Espectrometria de Massas por Ionização por Electrospray/métodosRESUMO
PURPOSE: Rocuronium (ROC) is a neuromuscular blocker mainly eliminated by biliary excretion dependent on organic anion transporting polypeptide 1A2 (OATP1A2) hepatocellular uptake. However, the influence of SLCO1A2 (gene encoding OATP1A2) genetic polymorphism on ROC pharmacokinetics was never described before. The objective of this work was to evaluate the influence of genetic polymorphisms of SLCO1A2 on the pharmacokinetics of rocuronium (ROC). METHODS: Patients undergoing elective surgeries under general anesthesia using rocuronium as a neuromuscular blocker were genotyped for SLCO1A2 polymorphisms in the coding region (41A>G, 382A>T, 404A>T, 502C>T, 516A>C, 559G>A, 830C>A, and 833delA) and in the promoter region (-1105G>A, -1032G>A, -715T>C, -361G>A, and -189_-188insA). Rocuronium pharmacokinetic parameters were estimated by non-compartmental analysis. RESULTS: None of the patients had heterozygous or homozygous variant of 404A>T, 382A>T, 502C>T, 833delA, 830C>A, 41A>G, and -715T>C. A linkage disequilibrium was found between -1105G>A and -1032G>A genotypes. Patients genotyped as -A or AA (n = 17) for SLCO1A2 -189_-188InsA showed reduced total clearance of ROC compared to patients genotyped as -/- (n = 13) (151.6 vs 207.1 mL/min, p ≤ 0.05). The pharmacokinetics parameters of ROC were not significantly different between other SLCO1A2 genotypes. CONCLUSION: SLCO1A2 -189_-188InsA polymorphism is related to the reduced clearance of rocuronium in patients submitted to elective surgeries under general anesthesia. TRIAL REGISTRATION: NCT 02399397 ( ClinicalTrials.gov ).
Assuntos
Androstanóis/farmacocinética , Fármacos Neuromusculares não Despolarizantes/farmacocinética , Transportadores de Ânions Orgânicos/genética , Adulto , Idoso , Androstanóis/sangue , Procedimentos Cirúrgicos Eletivos , Feminino , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Fármacos Neuromusculares não Despolarizantes/sangue , Polimorfismo de Nucleotídeo Único , RocurônioRESUMO
The liver and kidney functions of recipients of liver transplantation (LT) surgery with heart beating (HBD, n = 13) or living donors (LD, n = 9) with different cold ischemia times were examined during the neohepatic phase for the elimination of rocuronium bromide (ROC, cleared by liver and kidney) and tranexamic acid (TXA, cleared by kidney). Solid phase micro-extraction and LC-MS/MS was applied to determine the plasma concentrations of ROC and TXA, and creatinine was determined by standard laboratory methods. Metabolomics and the relative expressions of miR-122, miR-148a and γ-glutamyltranspeptidase (GGT), liver injury biomarkers, were also measured. The ROC clearance for HBD was significantly lower than that for LD (0.147 ± 0.052 vs. 0.265 ± 0.148 ml·min-1 ·g-1 liver) after intravenous injection (0.6 mg·kg-1 ). The clearance of TXA, a compound cleared by glomerular filtration, given as a 1 g bolus followed by infusion (10 mg·kg-1 ·h-1 ), was similar between HBD and LD groups (~ 1 ml·min-1 ·kg-1 ). The TXA clearance in both groups was lower than the GFR, showing a small extent of hepatorenal coupling. The miR-122 and miR-148a expressions were similar for the HBD and LD groups, whereas GGT expression was significantly increased for HBD. The lower ROC clearance and the higher GGT levels in the HBD group of longer cold ischemia times performed worse than the LD group during the neophase. Metabololmics further showed clusters of bile acids, phospholipids and lipid ω-oxidation products for the LD and HBD groups. In conclusion, ROC CL and GGT expression, and metabolomics could serve as sensitive indices of early graft function. Copyright © 2017 John Wiley & Sons, Ltd.
Assuntos
Falência Hepática , Transplante de Fígado , Doadores de Tecidos , Adulto , Idoso , Androstanóis/sangue , Androstanóis/farmacocinética , Biomarcadores/análise , Feminino , Humanos , Falência Hepática/genética , Falência Hepática/metabolismo , Masculino , Metabolômica , MicroRNAs/genética , Pessoa de Meia-Idade , Modelos Biológicos , Projetos Piloto , Rocurônio , Ácido Tranexâmico/sangue , Ácido Tranexâmico/farmacocinética , gama-Glutamiltransferase/genéticaRESUMO
BACKGROUND: The influence of preoperative rehydration on the action of rocuronium has not yet been investigated. OBJECTIVE: The objective is to evaluate the hypothesis that preoperative rehydration lowers arterial rocuronium plasma concentrations and changes its associated neuromuscular blocking effects during induction of anaesthesia. DESIGN: Randomised, single-blinded study. SETTING: A secondary hospital from October 2013 to July 2014. PATIENTS: In total, 46 men undergoing elective surgery were eligible to participate and were randomly allocated into two groups. Exclusion criteria were severe hepatic, renal or cardiovascular disorder; neuromuscular disease; history of allergy to rocuronium; BMI more than 30âkgâm; receiving medication known to influence neuromuscular function. INTERVENTION: Participants received 1500âml of oral rehydration solution (rehydration group) or none (control group) until 2 hours before anaesthesia. Arterial blood samples were obtained 60, 90 and 120âs and 30âmin after rocuronium (0.6âmgâkg) administration during total intravenous anaesthesia. Responses to 0.1-Hz twitch stimuli were measured at the adductor pollicis muscle using acceleromyography. MAIN OUTCOME MEASURES: Arterial plasma rocuronium concentrations. RESULTS: Arterial plasma rocuronium concentrations at 60, 90 and 120âs in the rehydration and control groups were 9.9 and 13.7, 6.8 and 9.5 and 6.2 and 8.1âµgâml, respectively (Pâ=â0.02, 0.003 and 0.02, respectively); the onset times in the rehydration and control groups were 92.0 and 69.5âs (Pâ=â0.01), and the times to twitch re-appearance were 25.3 and 30.4âmin (Pâ=â0.004), respectively. CONCLUSION: Preoperative rehydration significantly reduces arterial plasma rocuronium concentrations in the first 2 minutes after administration, prolonging the onset time and shortening the duration of effect. A higher dose or earlier administration should be considered for patients who receive preoperative rehydration. TRIAL REGISTRATION: Umin identifier: UMIN000011981.
Assuntos
Androstanóis/sangue , Anestesia Intravenosa/efeitos adversos , Procedimentos Cirúrgicos Eletivos/efeitos adversos , Hidratação/efeitos adversos , Fármacos Neuromusculares não Despolarizantes/sangue , Adulto , Androstanóis/administração & dosagem , Período de Recuperação da Anestesia , Anestesia Intravenosa/métodos , Desidratação/etiologia , Desidratação/terapia , Jejum/efeitos adversos , Humanos , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Período Pré-Operatório , Rocurônio , Método Simples-Cego , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
OBJECTIVE: To evaluate the impact of advanced age on rocuronium kinetic disposition in ASA I-III patients undergoing elective surgeries. METHODS: Young adult (20-50 years, n = 15) and elderly patients (65-85 years, n = 14) submitted to surgery under general anaesthesia were investigated. All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol. Rocuronium-induced neuromuscular block was monitored by train of four stimulations of the adductor muscle of the thumb on the ulnar nerve. The pharmacokinetic parameters were calculated by non-compartmental analysis. The relationship between rocuronium plasma concentration and the neuromuscular blockade was described by a sigmoidal Emax model. KEY-FINDINGS: Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 µg min/ml (mg/kg) vs 392.2 µg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults. The concentrations required to achieve 50% of maximum neuromuscular block (EC50) were similar for young adult (338.8 ng/ml) and elderly (462.7 ng/ml) patients (P > 0.05). CONCLUSIONS: Elderly patients showed increased AUC/D and reduced total Cl compared to young adult patients due to the age-related reduced renal function. Differences in the PK-PD properties of rocuronium in elderly population are due to changes in drug disposition rather than to alterations in the sensitivity to the drug.
Assuntos
Androstanóis/farmacocinética , Procedimentos Cirúrgicos Eletivos , Fármacos Neuromusculares não Despolarizantes/farmacocinética , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Androstanóis/administração & dosagem , Androstanóis/sangue , Anestesia Geral , Área Sob a Curva , Feminino , Humanos , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Modelos Biológicos , Monitoração Neuromuscular , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Fármacos Neuromusculares não Despolarizantes/sangue , Rocurônio , Adulto JovemRESUMO
The Wobbler mouse is an animal model for human motoneuron diseases, especially amyotrophic lateral sclerosis (ALS), used in the investigation of both pathology and therapeutic treatment. ALS is a fatal neurodegenerative disease, characterized by the selective and progressive death of motoneurons, leading to progressive paralysis. Previous limited studies have reported steroidal hormone dysregulation in Wobbler mouse and in ALS patients, suggesting endocrine dysfunctions which may be involved in the pathogenesis of the disease. In this study, we established a steroid profiling in brain, spinal cord, plasma, adrenal glands, and testes in 2-month-old male Wobbler mice and their littermates by gas chromatography coupled to mass spectrometry. Our results show in Wobbler mice the following: 1) a marked up-regulation of corticosterone levels in adrenal glands, plasma, spinal cord regions (cervical, thoracic, lumbar) and brain; 2) a strong decrease in T levels in the testis, plasma, spinal cord, and brain; and 3) increased levels of progesterone and especially of its reduced metabolites 5α-dihydroprogesterone, allopregnanolone, and 20α-dihydroprogesterone in the brain, spinal cord, and adrenal glands. Furthermore, Wobbler mice showed a hypothalamic-pituitary-gonadal hypoactivity. Interestingly, plasma concentrations of corticosterone and T correlate well with their respective levels in cervical spinal cord in both control and Wobbler mice. T down-regulation is probably the consequence of adrenal hyperactivity, and the up-regulation of progesterone and its reduced metabolites may correspond to an endogenous protective mechanism in response to motoneuron degeneration. Our findings suggest that increased levels of corticosterone and decreased levels of T in plasma could be a signature of motoneuron degeneration.
Assuntos
Esclerose Lateral Amiotrófica/metabolismo , 17-Cetosteroides/sangue , 17-Cetosteroides/metabolismo , Glândulas Suprarrenais/metabolismo , Esclerose Lateral Amiotrófica/sangue , Androstanóis/sangue , Androstanóis/metabolismo , Animais , Encéfalo/metabolismo , Corticosterona/sangue , Corticosterona/metabolismo , Modelos Animais de Doenças , Feminino , Cromatografia Gasosa-Espectrometria de Massas , Hormônio Liberador de Gonadotropina/metabolismo , Hormônio Luteinizante/sangue , Masculino , Camundongos , Neurônios Motores/metabolismo , Neurônios Motores/fisiologia , Pregnanolona/sangue , Pregnanolona/metabolismo , Progesterona/sangue , Progesterona/metabolismo , Medula Espinal/metabolismo , Testículo/metabolismo , Testosterona/sangue , Testosterona/metabolismoRESUMO
The utility of a circulatory three-compartment model for the assessment of tissue uptake kinetics is tested by comparison with the respective distributed models using pharmacokinetic data of rocuronium in patients These minimal physiologically based models have a common structure consisting of two subsystems representing the lung and the lumped systemic circulation, with two regions, the vascular and tissue space. The distributed models are based on either diffusion-limited tissue distribution, permeability-limited tissue uptake or the assumption of an empirical transit time density function. With a deviation in the estimate of the permeability-surface area product (PS) of about 18 %, the compartmental approach appears as a useful alternative on condition that a priori knowledge of cardiac output is included. It is also shown that the distribution clearance calculated from the parameters of a mammillary compartment model changes proportional to PS and can be used as an indirect measure of permeability-limited tissue uptake of drugs.
Assuntos
Androstanóis/farmacocinética , Modelos Biológicos , Fármacos Neuromusculares não Despolarizantes/farmacocinética , Androstanóis/sangue , Permeabilidade Capilar/fisiologia , Débito Cardíaco/fisiologia , Relação Dose-Resposta a Droga , Humanos , Cinética , Fármacos Neuromusculares não Despolarizantes/sangue , Rocurônio , Fatores de Tempo , Distribuição TecidualRESUMO
BACKGROUND: Rocuronium (Rb) is ideal for continuous infusion but has a widely variable duration of action. We investigated the distribution of Rb infusion in a steady state of optimal muscle relaxation and the relationship between the measured and predicted blood Rb concentrations in laparoscopic surgery. METHODS: Seventeen patients were anesthetized with propofol. Continuous Rb infusion was commenced at 7.5 µg/kg/min from 15 min after an initial Rb injection (0.6 mg/kg) and adjusted every 15 min to keep T1 within 3-10 %. Blood concentration was measured at the first onset of steady state, predicted concentration was calculated pharmacokinetically, and 25 % recovery time was measured. The distribution of the predicted concentration and infusion rate was plotted by histogram, the median value and 95th percentile were calculated, and the relationship between measured and predicted concentrations was analyzed by regression analysis. RESULTS: The rate during the stable state was 7.3 ± 2.1 µg/kg/min on average, 4 at minimum, 12 at maximum, and 12 at the 95th percentile. The predicted concentration was 1.7 ± 0.5 µg/ml on average, 0.8 at minimum, and 2.9 at maximum. The mean measured concentration was 1.4 ± 0.4 µg/ml. The predicted concentration was proportional to the measured concentration (y = 0.91x, r = 0.475; p < 0.001). A significant linear relationship was observed between the measured concentration and infusion rate (y = 0.64 + 0.11x, r = 0.618; p < 0.05). CONCLUSION: The measured blood concentration of Rb was comparable to the predicted value. Anesthesiologists can avoid overdose and attain a reliable muscle relaxant effect by maintaining a continuous dose by titration according to individual differences under muscle relaxant monitoring.
Assuntos
Androstanóis/administração & dosagem , Anestésicos Intravenosos/administração & dosagem , Piperidinas/administração & dosagem , Propofol/administração & dosagem , Adulto , Idoso , Androstanóis/sangue , Anestesia Intravenosa , Feminino , Humanos , Laparoscopia/métodos , Masculino , Pessoa de Meia-Idade , Relaxamento Muscular/efeitos dos fármacos , Remifentanil , RocurônioRESUMO
Sugammadex is the first selective relaxant binding agent. It allows rapid reversal of any degree of neuromuscular blockade induced by steroidal neuromuscular blocking agents. Sugammadex acts by encapsulation of the neuromuscular blocking agent. This prevents the drug from acting on prejunctional and postjunctional nicotinic receptors, allowing acetylcholine to activate these receptors, and resulting in reversal of the neuromuscular blockade. Objective monitoring of the degree of neuromuscular blockade is strongly recommended to determine the optimal dose of sugammadex. A good understanding of the concept behind sugammadex is essential in order to use this reversal agent in clinical practice.
Assuntos
Androstanóis/antagonistas & inibidores , Recuperação Demorada da Anestesia/tratamento farmacológico , Fármacos Neuromusculares não Despolarizantes/antagonistas & inibidores , Brometo de Vecurônio/antagonistas & inibidores , gama-Ciclodextrinas/farmacologia , Acetilcolina/metabolismo , Acetilcolina/fisiologia , Androstanóis/administração & dosagem , Androstanóis/sangue , Ligação Competitiva , Relação Dose-Resposta a Droga , Humanos , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Fármacos Neuromusculares não Despolarizantes/sangue , Concentração Osmolar , Receptores Nicotínicos/efeitos dos fármacos , Receptores Nicotínicos/fisiologia , Rocurônio , Sugammadex , Brometo de Vecurônio/administração & dosagem , Brometo de Vecurônio/sangue , gama-Ciclodextrinas/administração & dosagem , gama-Ciclodextrinas/uso terapêuticoRESUMO
A high-throughput method using solid-phase microextraction coupled to liquid chromatography-tandem mass spectrometry (SPME-LC-MS/MS) for determination of tranexamic acid and rocuronium bromide in human plasma was developed and validated. Standard analytical approaches employ acidification of the sample due to the instability of rocuronium bromide in collected plasma samples. However, acidification affects the binding equilibrium of the drug and consequently no information on the free/bound concentration can be obtained. Contrary to these protocols, the proposed method requires minimum sample handling and no ion pairing and/or derivatization procedure. A weak cation exchange coating was chosen as the best extracting phase for selected drugs, guaranteed a good recovery, minimum carry-over, reusability and reproducibility. SPME procedure met all Food and Drug Administration acceptance criteria for bioanalytical assays at three concentration levels, for both selected drugs. Post-extraction addition experiments showed that matrix effect was less than ±3%. Here, a weak cation exchange thin-film solid-phase microextraction (WCX TF-SPME) approach is presented, offering effective cleanup procedure and full quantitation of the drugs in plasma, undoubtedly one the most challenging matrices with regards to its complexity. In addition, the 96-well plate format of WCX TF-SPME system provides considerable advantages, such as high throughput analysis for up to 96 samples in 35min (22s/sample), requirement of small amounts of plasma samples (0.8mL), and a simple sample preparation protocol, all of which shows a promise for possible on-site application in hospitals to monitor concentrations of the drugs in close to real time.
Assuntos
Androstanóis/sangue , Androstanóis/química , Cromatografia Líquida/métodos , Microextração em Fase Sólida/métodos , Espectrometria de Massas em Tandem/métodos , Ácido Tranexâmico/sangue , Ácido Tranexâmico/química , Humanos , Reprodutibilidade dos Testes , RocurônioRESUMO
This paper presents a model based switching control strategy to drive the neuromuscular blockade (NMB) level of patients undergoing general anesthesia to a predefined reference. A single-input single-output Wiener system with only two parameters is used to model the effect of two different muscle relaxants, atracurium and rocuronium, and a switching controller is designed based on a bank of total system mass control laws. Each of such laws is tuned for an individual model from a bank chosen to represent the behavior of the whole population. The control law to be applied at each instant corresponds to the model whose NMB response is closer to the patient's response. Moreover a scheme to improve the reference tracking quality based on the analysis of the patient's response, as well as, a comparison between the switching strategy and the Extended Kalman Kilter (EKF) technique are presented. The results are illustrated by means of several simulations, where switching shows to provide good results, both in theory and in practice, with a desirable reference tracking. The reference tracking improvement technique is able to produce a better reference tracking. Also, this technique showed a better performance than the (EKF). Based on these results, the switching control strategy with a bank of total system mass control laws proved to be robust enough to be used as an automatic control system for the NMB level.
Assuntos
Androstanóis/administração & dosagem , Androstanóis/farmacocinética , Monitoramento de Medicamentos/métodos , Quimioterapia Assistida por Computador/tendências , Modelos Biológicos , Bloqueio Nervoso/métodos , Androstanóis/sangue , Simulação por Computador , Retroalimentação Fisiológica/fisiologia , Humanos , Taxa de Depuração Metabólica , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Fármacos Neuromusculares não Despolarizantes/sangue , Fármacos Neuromusculares não Despolarizantes/farmacocinética , RocurônioRESUMO
BACKGROUND: Anesthetics are variable in patients with obstructive jaundice. The minimum alveolar concentration awake of desflurane is reduced in patients with obstructive jaundice, while it has no effect on pharmacodynamics and pharmacokinetics of propofol. In this study, we investigated the influence of obstructive jaundice on the pharmacodynamics and blood concentration of rocuronium. METHODS: Included in this study were 26 control patients and 27 patients with obstructive jaundice. Neuromuscular block of rocuronium was monitored by acceleromyography. Onset time, spontaneous recovery of the height of twitch first (T1) to 25% of the final T1 value (Duration 25%, Dur 25%), recovery index (RI), and spontaneous recovery of train-of-four (TOF) ratios to 70% were measured. The plasma rocuronium concentrations were determined by high performance liquid chromatography using berberine as an internal standard. RESULTS: There was no significant difference in onset time between the two groups. The Dur 25%, the recovery index and the time of recovery of the TOF ratios to 70% were all prolonged in the obstructive jaundice group compared with the control group. The plasma concentration of rocuronium at 60, 90 and 120 min after bolus administration was significantly higher in the obstructive jaundice group. CONCLUSIONS: The neuromuscular blockade by rocuronium is prolonged in obstructive jaundice patients, and therefore precautions should be taken in case of postoperative residual neuromuscular block. The possible reason is impedance of rocuronium excretion due to biliary obstruction and increased plasma unbound rocuronium because of free bilirubin competing with it for albumin binding.
Assuntos
Androstanóis/farmacocinética , Icterícia Obstrutiva/sangue , Icterícia Obstrutiva/metabolismo , Adulto , Androstanóis/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Bloqueio Neuromuscular , RocurônioRESUMO
A rapid, accurate and sensitive liquid chromatography-tandem mass spectrometry method has been developed for the determination of a quaternary nitrogen muscle relaxant, rocuronium, in human blood. The procedure involves protein precipitation with chloroform and trichloroacetic acid, and purification using methanol. The chromatography was performed using a phenyl-hexyl column (150 × 2.0 mm i.d., 3 µm; Phenomenex) with a mobile phase consisting of 5 mM ammonium formate (pH 3.0) and acetonitrile. Multiple reaction monitoring was used for quantification. The assay was linear over a concentration range of 4-500 ng/mL for rocuronium with R(2) ≥ 0.998. The recoveries for this compound ranged from 96.0 to 109.1%. The intra-day and inter-day precision was less than 10.5% and the accuracy ranged from 106.6 to 114.9%. The validated method was applied to quantify the content of rocuronium in blood and a variety of tissues of a victim suspected of overdose. In conclusion, the method was successfully applied for the analysis of rocuronium in biological samples for forensic toxicology.
Assuntos
Androstanóis/análise , Androstanóis/sangue , Cromatografia Líquida de Alta Pressão/métodos , Espectrometria de Massas em Tandem/métodos , Adulto , Androstanóis/farmacocinética , Feminino , Humanos , Limite de Detecção , Reprodutibilidade dos Testes , Rocurônio , Espectrometria de Massas por Ionização por Electrospray/métodos , Distribuição TecidualRESUMO
17α-ethynyl-5α-androstane-3α, 17ß-diol (HE3235, Apoptone) is an orally bioavailable synthetic analogue of 3ß-androstanediol, that is active in rodent models of prostate and breast cancer, and is in Phase IIa clinical trials for the treatment of early- and late-stage prostate cancer. In preparation for clinical studies, nuclear hormone receptor and P450 interactions for HE3235 and major metabolites were characterized in vitro, and pharmacokinetics and metabolite profiles were studied in rodents, dogs, and monkeys. Four-week safety studies conducted in rats and dogs indicated a substantial margin of safety for clinical use, and no evidence of electrocardiographic or neurological effects, although anorexia, thrombocytopenia, and hypokalemia were identified as potentially dose-limiting toxicities at superpharmacological exposures. Pharmacokinetics and drug metabolism have been studied in prostate cancer patients.
Assuntos
Androstanóis/farmacocinética , Antineoplásicos Hormonais/farmacocinética , Sistema Enzimático do Citocromo P-450/metabolismo , Neoplasias da Próstata/tratamento farmacológico , Administração Oral , Androstanóis/administração & dosagem , Androstanóis/sangue , Androstanóis/toxicidade , Androstenodiona/sangue , Animais , Antineoplásicos Hormonais/administração & dosagem , Antineoplásicos Hormonais/sangue , Antineoplásicos Hormonais/toxicidade , Biotransformação , Linhagem Celular Tumoral , Cromatografia Líquida , Inibidores das Enzimas do Citocromo P-450 , Sistema Enzimático do Citocromo P-450/biossíntese , Desidroepiandrosterona/sangue , Cães , Esquema de Medicação , Indução Enzimática , Inibidores Enzimáticos/farmacologia , Feminino , Humanos , Macaca fascicularis , Masculino , Metabolômica , Camundongos , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/enzimologia , Neoplasias da Próstata/metabolismo , Neoplasias da Próstata/patologia , Ratos , Ratos Sprague-Dawley , Receptores Citoplasmáticos e Nucleares/efeitos dos fármacos , Receptores Citoplasmáticos e Nucleares/genética , Receptores Citoplasmáticos e Nucleares/metabolismo , Especificidade da Espécie , Espectrometria de Massas em Tandem , Testosterona/sangue , Ativação Transcricional/efeitos dos fármacos , TransfecçãoRESUMO
BACKGROUND: Epilepsy in women may be associated with reproductive disorders and alterations in serum steroid levels. Some steroids can be induced by epilepsy and/or treatment with antiepileptic drugs; however, there are still limited data available concerning this effect on the levels of other neuroactive steroid metabolites such as 3a-hydroxy-5a/b-reduced androstanes. AIM: To evaluate steroid alterations in women with epilepsy (WWE) on lamotrigine monotherapy. SUBJECTS AND METHODS: Eleven WWE and 11 age-matched healthy women underwent blood sampling in both phases of their menstrual cycles (MCs). The steroid metabolome, which included 30 unconjugated steroids, 17 steroid polar conjugates, gonadotropins, and sex hormone-binding globulin (SHBG), was measured using gas chromatography-mass spectrometry (GC-MS) and radioimmunoassay (RIA). RESULTS: WWE had lower cortisol levels (status p<0.001), but elevated levels of unconjugated 17-hydroxypregnenolone (status p<0.001). Progesterone was higher in the follicular menstrual phase (FP) in WWE than in the controls (status×menstrual phase p<0.05, Bonferroni multiple comparisons p<0.05), whereas 17-hydroxyprogesterone was higher in WWE in both menstrual phases (status p<0.001). The steroid conjugates were mostly elevated in WWE. The levels of 5α/ß-reduced androstanes in WWE that were significantly higher than the controls were etiocholanolone (status p<0.001), 5α-androstane-3α,17ß-diol (status p<0.001), and the 5α/ß-reduced androstane polar conjugates (status p<0.001). CONCLUSIONS: WWE showed a trend toward higher circulating 3α-hydroxy-5α/ß-reduced androstanes, increased activity of 17α-hydroxylase/17,20 lyase in the Δ(5)-steroid metabolic pathway, and increased levels of the steroid polar conjugates.
Assuntos
17-alfa-Hidroxipregnenolona/sangue , Androstanos/sangue , Androstanos/metabolismo , Anticonvulsivantes/uso terapêutico , Epilepsia/tratamento farmacológico , Epilepsia/metabolismo , Triazinas/uso terapêutico , Adulto , Androstanóis/sangue , Anticonvulsivantes/efeitos adversos , Feminino , Humanos , Lamotrigina , Metaboloma , Esteroide 17-alfa-Hidroxilase/sangue , Triazinas/efeitos adversosRESUMO
The time-course of the neuromuscular blocking effect of rocuronium depends on circulatory mixing and the rate of distribution into the interstitial space. In order to quantitatively evaluate these processes, a physiologically meaningful model of distribution kinetics based on circulatory transport and interstitial diffusion, was fitted to rocuronium disposition data in 10 patients using a population approach. Information on cardiac output and circulatory mixing was obtained from the kinetics of indocyanine green (ICG), which was injected simultaneously with rocuronium. As a compromise between physiological reality and parameter identifiability, the organs of the systemic circulation were lumped into a heterogeneous subsystem, described by an axially distributed model of extravascular diffusion. Diffusion into the interstitial space determines the rate of rocuronium distribution in the body (diffusional time constant 89 min). The resulting whole body distribution kinetics depends both on cardiac output and on the apparent permeability surface area product (0.16 l/min). The analysis of the ICG data revealed that heterogeneity of blood transit time through the systemic circulation decreased and that cardiopulmonary volume increased, respectively, with cardiac output. The approach should be useful for studying the effect of disease states on distribution kinetics of drugs.
Assuntos
Androstanóis/farmacocinética , Modelos Cardiovasculares , Fármacos Neuromusculares não Despolarizantes/farmacocinética , Androstanóis/sangue , Transporte Biológico , Débito Cardíaco/fisiologia , Corantes/farmacocinética , Difusão , Feminino , Humanos , Verde de Indocianina/farmacocinética , Fármacos Neuromusculares não Despolarizantes/sangue , RocurônioRESUMO
BACKGROUND: Clearance of rocuronium in the neohepatic period may be a criterion for graft function during orthotopic liver transplantation (OLT). Our goal was to demonstrate that changes in rocuronium elimination are caused mainly by variations in blood volume at reperfusion. We have explored the influence on rocuronium plasma concentrations of changing the order of vascular unclamping at graft reperfusion. METHODS: Thirty patients were randomized at graft reperfusion: initial arterial revascularization (IAR; n = 14) wherein the hepatic artery was released first, and initial portal revascularization (IPR; n = 16) wherein the portal vein was released first. Tracheal intubation was facilitated by rocuronium (1 mg/kg) with an infusion initiated at 0.25 mg kg(-1) h(-1) to maintain a response to the first stimulus of the train of four <25% of controls. Rocuronium plasma concentrations (RPC) were measured throughout the transplantation. RESULTS: No differences were observed in rocuronium consumption at different stages. RPCs decreased after reperfusion, with primarily portal unclamping responsible. In 6 patients of the IAR group and 5 patients of the IPR group, RPC at 60 minutes after reperfusion was higher than previous values. Indicators of graft dysfunction among those 11 did not differ from the other patients. Two patients in the IPR group required retransplantation without any relation to changes in RPCs. CONCLUSION: The increase of blood flow produced by portal vein unclamping influenced RPCs; no relation was observed between RPCs and graft outcomes.
Assuntos
Transplante de Fígado/métodos , Fármacos Neuromusculares não Despolarizantes/farmacocinética , Reperfusão , Adulto , Idoso , Androstanóis/administração & dosagem , Androstanóis/sangue , Constrição , Feminino , Artéria Hepática/cirurgia , Humanos , Infusões Intravenosas , Intubação/métodos , Circulação Hepática/fisiologia , Masculino , Pessoa de Meia-Idade , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Fármacos Neuromusculares não Despolarizantes/sangue , Veia Porta/cirurgia , Reperfusão/métodos , RocurônioRESUMO
Significant progress in the management of aminosteroid nondepolarizing neuromuscular blockers will follow the introduction of sugammadex (Org 25969). Safety and rapid recovery of muscle force will improve and the adverse effects of acetylcholinesterase inhibitors will be avoided. Sugammadex is a modified gamma-cyclodextrin agent developed for the specific reversal of rocuronium and, to a lesser extent, vecuronium. This novel drug functions by means of encapsulation (chelation). Sugammadex was recently approved by the European Medicines Evaluation Agency and became available in Spain in 2009, leading to a series of changes related to patient safety and surgical conditions. We review the literature on sugammadex published to date.